These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30562195)

  • 1. Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial).
    Waissi F; Kist JW; Lodewijk L; de Wit AG; van der Hage JA; van Dalen T; de Keizer B; Valk GD; Borel Rinkes IHM; Vriens MR
    Clin Nucl Med; 2019 Apr; 44(4):272-275. PubMed ID: 30562195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
    Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
    Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.
    Borget I; Corone C; Nocaudie M; Allyn M; Iacobelli S; Schlumberger M; De Pouvourville G
    Eur J Endocrinol; 2007 May; 156(5):531-8. PubMed ID: 17468188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH.
    Emmanouilidis N; Müller JA; Jäger MD; Kaaden S; Helfritz FA; Güner Z; Kespohl H; Knitsch W; Knapp WH; Klempnauer J; Scheumann GF
    Eur J Endocrinol; 2009 Nov; 161(5):763-9. PubMed ID: 19687168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
    Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
    Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
    Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective.
    Mernagh P; Suebwongpat A; Silverberg J; Weston A
    Value Health; 2010; 13(2):180-7. PubMed ID: 19818064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
    Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
    Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective.
    Mernagh P; Campbell S; Dietlein M; Luster M; Mazzaferri E; Weston AR
    Eur J Endocrinol; 2006 Sep; 155(3):405-14. PubMed ID: 16914594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.
    van der Horst-Schrivers AN; Sluiter WJ; Muller Kobold AC; Wolffenbuttel BH; Plukker JT; Bisschop PH; de Klerk JM; Al Younis I; Lips P; Smit JW; Brouwers AH; Links TP
    PLoS One; 2015; 10(3):e0120184. PubMed ID: 25793762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
    Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
    Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
    Lawal IO; Nyakale NE; Harry LM; Lengana T; Mokgoro NP; Vorster M; Sathekge MM
    Nucl Med Commun; 2017 Mar; 38(3):222-227. PubMed ID: 28002173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.
    Forrer F; Fischer GF; Maas O; Giovanella L; Hoffmann M; Iakovou I; Luster M; Mihailovic J; Petranovic Ovčariček P; Vrachimis A; Zerdoud S; Putora PM
    Oncology; 2022; 100(2):74-81. PubMed ID: 34788758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.